# A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease

> **NCT00283959** · PHASE2 · COMPLETED · sponsor: **Amicus Therapeutics** · enrollment: 4 (actual)

## Conditions studied

- Fabry Disease

## Interventions

- **DRUG:** migalastat HCl

## Key facts

- **NCT ID:** NCT00283959
- **Lead sponsor:** Amicus Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06-27
- **Primary completion:** 2008-05-08
- **Final completion:** 2008-05-08
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2018-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00283959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00283959, "A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT00283959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*